<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Res Protoc</journal-id><journal-id journal-id-type="iso-abbrev">JMIR Res Protoc</journal-id><journal-id journal-id-type="publisher-id">ResProt</journal-id><journal-title-group><journal-title>JMIR Research Protocols</journal-title></journal-title-group><issn pub-type="epub">1929-0748</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28720557</article-id><article-id pub-id-type="pmc">5539386</article-id><article-id pub-id-type="publisher-id">v6i7e134</article-id><article-id pub-id-type="doi">10.2196/resprot.7327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group><subj-group subj-group-type="article-type"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Comparing Mobile Health Strategies to Improve Medication Adherence for Veterans With Coronary Heart Disease (Mobile4Meds): Protocol for a Mixed-Methods Study</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Eysenbach</surname><given-names>Gunther</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Kayser</surname><given-names>John</given-names></name></contrib><contrib contrib-type="reviewer"><name><surname>Schwiebert</surname><given-names>Loren</given-names></name></contrib></contrib-group><contrib-group><contrib id="contrib1" contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>Linda G</given-names></name><degrees>PhD, MSc, FNP-C</degrees><xref ref-type="aff" rid="aff1">1</xref><address><institution>Department of Veterans Affairs</institution><institution>Community Health Systems</institution><institution>University of California, San Francisco</institution><addr-line>2 Koret Way, Box 0608</addr-line><addr-line>Room 531A</addr-line><addr-line>San Francisco, CA, 94143</addr-line><country>United States</country><phone>1 415 502 6616</phone><fax>1 415 476 6042</fax><email>linda.park@ucsf.edu</email></address><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9894-4039</contrib-id></contrib><contrib id="contrib2" contrib-type="author"><name><surname>Collins</surname><given-names>Eileen G</given-names></name><degrees>PhD, RN</degrees><xref ref-type="aff" rid="aff2">2</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1302-7264</contrib-id></contrib><contrib id="contrib3" contrib-type="author"><name><surname>Shim</surname><given-names>Janet K</given-names></name><degrees>PhD, MPP</degrees><xref ref-type="aff" rid="aff3">3</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4597-7961</contrib-id></contrib><contrib id="contrib4" contrib-type="author"><name><surname>Whooley</surname><given-names>Mary A</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5943-0078</contrib-id></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Veterans Affairs</institution>
<institution>Community Health Systems</institution>
<institution>University of California, San Francisco</institution>
<addr-line>San Francisco, CA</addr-line>
<country>United States</country></aff><aff id="aff2">
<sup>2</sup>
<institution>Edward Hines Jr., VA Hospital</institution>
<institution>Department of Biobehavioral Health Science</institution>
<institution>University of Illinois at Chicago</institution>
<addr-line>Chicago, IL</addr-line>
<country>United States</country></aff><aff id="aff3">
<sup>3</sup>
<institution>University of California, San Francisco</institution>
<institution>Social and Behavioral Sciences</institution>
<addr-line>San Francisco, CA</addr-line>
<country>United States</country></aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Veterans Affairs</institution>
<institution>Department of Medicine, Epidemiology and Biostatistics</institution>
<institution>University of California, San Francisco</institution>
<addr-line>San Francisco, CA</addr-line>
<country>United States</country></aff><author-notes><corresp>Corresponding Author: Linda G Park
<email>linda.park@ucsf.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>18</day><month>7</month><year>2017</year></pub-date><volume>6</volume><issue>7</issue><elocation-id>e134</elocation-id><history><date date-type="received"><day>14</day><month>1</month><year>2017</year></date><date date-type="rev-request"><day>2</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>10</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9;Linda G Park, Eileen G Collins, Janet K Shim, Mary A Whooley. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 18.07.2017.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p><!--CREATIVE COMMONS-->This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="http://www.researchprotocols.org,">http://www.researchprotocols.org,</ext-link> as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://www.researchprotocols.org/2017/7/e134/"/><abstract><sec sec-type="background"><title>Background</title><p>Adherence to antiplatelet medications is critical to prevent life threatening complications (ie, stent thrombosis) after percutaneous coronary interventions (PCIs), yet rates of nonadherence range from 21-57% by 12 months. Mobile interventions delivered via text messaging or mobile apps represent a practical and inexpensive strategy to promote behavior change and enhance medication adherence.</p></sec><sec sec-type="objective"><title>Objective</title><p>The Mobile4Meds study seeks to determine whether text messaging or a mobile app, compared with an educational website control provided to all Veterans, can improve adherence to antiplatelet therapy among patients following acute coronary syndrome (ACS) or PCI. The three aims of the study are to: (1) determine preferences for content and frequency of text messaging to promote medication adherence through focus groups; (2) identify the most patient-centered app that promotes adherence, through a content analysis of all commercially available apps for medication adherence and focus groups centered on usability; and (3) compare adherence to antiplatelet medications in Veterans after ACS/PCI via a randomized clinical trial (RCT).</p></sec><sec sec-type="methods"><title>Methods</title><p>We will utilize a mixed-methods design that uses focus groups to achieve the first and second aims (N=32). Patients will be followed for 12 months after being randomly assigned to one of three arms: (1) customized text messaging, (2) mobile app, or (3) website-control groups (N=225). Medication adherence will be measured with electronic monitoring devices, pharmacy records, and self-reports.</p></sec><sec sec-type="results"><title>Results</title><p>Enrollment for the focus groups is currently in progress. We expect to enroll patients for the RCT in the beginning of 2018.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Determining the efficacy of mobile technology using a Veteran-designed protocol to promote medication adherence will have a significant impact on Veteran health and public health, particularly for individuals with chronic diseases that require strict medication adherence.</p></sec><sec sec-type="Trial Registration"><title>Trial Registration</title><p>ClinicalTrials.gov NCT03022669</p></sec></abstract><kwd-group><kwd>text messaging</kwd><kwd>mobile application</kwd><kwd>mobile health</kwd><kwd>cardiovascular disease</kwd><kwd>medication</kwd><kwd>adherence</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><sec><title>Coronary Heart Disease and Medication Adherence</title><p>Coronary heart disease is the leading cause of death in Veterans and affects 15.5 million people in the United States [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>]. Although coronary heart disease claims the lives of one out of every seven Americans [<xref rid="ref2" ref-type="bibr">2</xref>], the decline in acute coronary syndrome (ACS) and coronary heart disease-related deaths over the past four decades has been attributed to the availability of critical pharmacologic and invasive therapies (ie, percutaneous coronary intervention [PCI]) [<xref rid="ref3" ref-type="bibr">3</xref>-<xref rid="ref6" ref-type="bibr">6</xref>]. After PCI with drug-eluting stents, premature discontinuation of antiplatelet (thienopyridine) medications is strongly associated with in-stent thrombosis, leading to myocardial infarction (MI) and death [<xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref8" ref-type="bibr">8</xref>]. Despite the critical nature of taking antiplatelet medications to prevent life-threatening complications, one in seven MI patients treated with drug-eluting stents no longer take antiplatelet medications at 30 days [<xref rid="ref8" ref-type="bibr">8</xref>].</p><p>Medication nonadherence is a pervasive public health problem among Veterans and non-Veterans [<xref rid="ref9" ref-type="bibr">9</xref>-<xref rid="ref12" ref-type="bibr">12</xref>]; however, Veterans suffer from increased morbidity and mortality from chronic diseases compared to non-Veterans [<xref rid="ref13" ref-type="bibr">13</xref>]. Medication nonadherence is the number one problem in treating illnesses, as more than half of individuals with chronic diseases do not take any or all of their medications correctly [<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref15" ref-type="bibr">15</xref>]. Medication nonadherence in patients with coronary heart disease is closely linked to adverse clinical outcomes such as rehospitalization and mortality [<xref rid="ref16" ref-type="bibr">16</xref>-<xref rid="ref18" ref-type="bibr">18</xref>]; therefore, effective strategies are needed to improve adherence behaviors. Moreover, medication nonadherence results in an estimated US $290 billion in health care costs in the United States and is a tremendous burden on the health care system [<xref rid="ref19" ref-type="bibr">19</xref>]. Mobile technology may represent an effective strategy to improve medication adherence during the critical time period of one year post-ACS/PCI.</p></sec><sec><title>Mobile Health</title><p>In the past decade, mobile health (mHealth) has been introduced as a mechanism to enhance medication adherence and demonstrates strong potential to promote behavior change. The use of technology can facilitate adoption and integration of medication adherence by promoting behavioral strategies via health messaging, emphasizing healthy habits, tracking goals, and giving incentives for behavior change [<xref rid="ref20" ref-type="bibr">20</xref>]. While other behavioral and educational strategies have had disappointing results in adherence and treatment outcomes over many decades [<xref rid="ref21" ref-type="bibr">21</xref>,<xref rid="ref22" ref-type="bibr">22</xref>], the use of technology may provide an innovative, practical, personalized, and inexpensive approach to promote medication adherence. Diverse solutions are required with tailored theory-based interventions for different populations and conditions because the reasons for medication nonadherence are complex and multifactorial [<xref rid="ref23" ref-type="bibr">23</xref>,<xref rid="ref24" ref-type="bibr">24</xref>]. Experts agree that a patient-centered approach is critical to increase patients&#x02019; knowledge about medication management [<xref rid="ref25" ref-type="bibr">25</xref>].</p><p>Both text messaging and mobile apps are two popular forms of mHealth that provide convenient, inexpensive, and nonintrusive engagement with individuals. The use of mobile technology can particularly benefit those who have significant barriers to taking medications, such as confusion about which medications to take, forgetfulness, and lack of social support. Text messaging is more widely used by all age groups; however, mobile apps offer many more features than text messaging, and can harness the full sensing and computational capacity of mobile devices to collect and analyze health-related data in real time to deliver health and behavioral interventions [<xref rid="ref20" ref-type="bibr">20</xref>,<xref rid="ref26" ref-type="bibr">26</xref>].</p><p>Text messaging is popular, fast, direct, efficient, user-friendly, traceable, and provides easy data transfer [<xref rid="ref27" ref-type="bibr">27</xref>]. Text messaging is also nonintrusive, relatively simple, and lower in cost compared to mobile voice communication [<xref rid="ref28" ref-type="bibr">28</xref>]. In a systematic review of medication adherence studies using text messaging, we found that most interventions (18/29) resulted in improved medication adherence [<xref rid="ref29" ref-type="bibr">29</xref>]. This review did not examine any studies related to coronary heart disease, but gaps in the literature were discussed, such as understanding factors that are needed to maintain engagement (eg, content and frequency of text messaging). In contrast to text messaging, apps can offer interactivity, gaming, and feedback. Apps have the advantages of delivering interventions to an unlimited number of individuals in a cost-effective manner with favorable cost utility [<xref rid="ref30" ref-type="bibr">30</xref>]. While Internet interventions can be delivered via traditional desktop and laptop computers, users have the capacity to interact with mobile interventions more frequently and in the context of the behavior of interest [<xref rid="ref31" ref-type="bibr">31</xref>]. The trend of desktop use for research/program interventions is sharply declining in our current generation, given that most people carry and access their mobile phones throughout the day for various reasons. Using real-time sensing technologies available on mobile phones, health behavioral change interventions can be delivered based on time/location, psychological state, physiological state, social context, activity level, and patterns [<xref rid="ref32" ref-type="bibr">32</xref>].</p></sec><sec><title>Preliminary Studies</title><p>In a pilot randomized controlled trial (RCT) from 2012-2013, we compared antiplatelet and statin adherence among patients with coronary heart disease in a 30-day study who received: (1) text messaging for medication reminders and education, (2) educational text messaging only, or (3) no text messaging [<xref rid="ref33" ref-type="bibr">33</xref>]. Among 90 patients (76% male, mean age 59.2 years), electronic devices revealed that patients who received text messaging for antiplatelets had a higher percentage of correct doses taken (<italic>P</italic>=0.02), percentage number of doses taken (<italic>P</italic>=0.01), and percentage of prescribed doses taken on schedule (<italic>P</italic>=0.01) [<xref rid="ref33" ref-type="bibr">33</xref>]. Text messaging response rates were higher for antiplatelets than statins (<italic>P</italic>=0.005), and self-reported adherence revealed no significant differences among groups [<xref rid="ref33" ref-type="bibr">33</xref>]. We concluded that the use of text messaging for the medication reminders/education and education text messaging only groups (compared to no text messaging for the control group) increased adherence to antiplatelet therapy by 15% to 17%, respectively. We established feasibility and high satisfaction and concluded that mHealth interventions show promise in promoting medication adherence.</p></sec><sec><title>Aims</title><p>The proposed research study, Mobile4Meds, seeks to determine whether text messaging or a mobile app (compared with an educational website control provided to all Veterans) can improve adherence to antiplatelet therapy among patients post-ACS/PCI. There are three topics and aims of this proposed study. First, using <italic>Text Messaging</italic> we aim to determine preferences for content and frequency of text messaging to promote medication adherence. Second, using <italic>Mobile Apps</italic> we aim to identify the most patient-centered (user-friendly, engaging, personalized) mobile app that promotes medication adherence with stratification by low/high mobile phone use and sex. Finally, we aim to examine <italic>Medication Adherence</italic> by comparing adherence to antiplatelet medications upon hospital discharge from ACS/PCI via: (1) text messaging, (2) mobile app, or (3) website-control. <xref ref-type="fig" rid="figure1">Figure 1</xref> illustrates the aims, objectives, and outcomes of the proposed research study. Our long-term goal is to conduct a multi-site full scale RCT to determine clinical outcomes of emergency department utilization, rehospitalization, and cardiovascular (and all-cause) morbidity and mortality.</p><fig id="figure1" position="float"><label>Figure 1</label><caption><p>Aims, objectives, and outcomes.</p></caption><graphic xlink:href="resprot_v6i7e134_fig1"/></fig></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Theoretical Framework/Behavioral Change Model</title><p>To date, most mHealth studies have not been based on behavioral health theories [<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref31" ref-type="bibr">31</xref>]. In a systematic review of text messaging studies on medication adherence in various acute and chronic conditions, we found that only 5 of 29 studies used theory to guide research [<xref rid="ref29" ref-type="bibr">29</xref>]. Numerous precipitating factors and barriers affect medication adherence, and this complex process can be better understood when examining theoretical relationships and process. The conceptual model that explains the relationship between variables in this study is depicted in <xref ref-type="fig" rid="figure2">Figure 2</xref>. No single theory can completely explain the processes that lead to medication adherence, so we will use a theory-informed approach to complete the aims for this study. We will explore the general components of theory that are closely linked with behavioral change interventions (eg, perceived norms/threats, health beliefs, self-efficacy, cues to actions).</p><fig id="figure2" position="float"><label>Figure 2</label><caption><p>Conceptual model of behavior change for medication adherence.</p></caption><graphic xlink:href="resprot_v6i7e134_fig2"/></fig><fig id="figure3" position="float"><label>Figure 3</label><caption><p>Overview of study structure and sample. FG: focus group.</p></caption><graphic xlink:href="resprot_v6i7e134_fig3"/></fig></sec><sec><title>Research Design</title><p>Mobile4Meds is a mixed-methods study using both qualitative and quantitative research methods. Engaging patients initially through qualitative methods will provide opportunities for: (1) better translation, dissemination, and use of research results; (2) better evidence to inform guidelines; (3) targeted quality improvement; and (4) using research to address concerns of diverse patients [<xref rid="ref34" ref-type="bibr">34</xref>]. <xref ref-type="fig" rid="figure3">Figure 3</xref> provides an overview of the study structure and participants involved in each of the aims.</p></sec><sec><title>Aim 1: Text Messaging Focus Groups</title><sec><title>Design, Sample, Setting</title><p>We will use focus groups to fulfill the objectives of Aim 1. Each focus group will have 6-8 participants, which is a size that allows for easy exchanges of ideas and a diversity of perspectives to be represented. We will recruit a convenience sample of 24-32 participants for four focus groups. Aims 1 and 2 will include the same participants who will attend a total of four focus group sessions (<xref ref-type="fig" rid="figure3">Figure 3</xref>).</p><p>The participants from San Francisco Veterans Affairs Medical Center (SFVAMC) are likely to be predominantly male; therefore, we will likely recruit one group of female Veterans from SFVAMC and one focus group of female non-Veterans from John Muir Medical Center (JMMC) in the East Bay. The four groups will account for variability in mobile phone use (low/high) and sex. Inclusion criteria for Aims 1 and 2 include: (1) &#x0003e;21 years of age, (2) history of ACS or PCI within one year, and (3) current/former antiplatelet (thienopyridine) prescription. Exclusion criteria are: (1) cognitive impairment, and (2) lack of English proficiency/literacy.</p></sec><sec><title>Methods</title><sec><title>Preliminary Development of Text Messaging</title><p>We will explore different content for the development of a text messaging intervention to determine the ideal tailored messages for delivery in the RCT (Aim 3). After studying various behavioral change theories and frameworks, we will create a text messaging intervention with the underpinnings of common behavioral change theories. A library of 80-100 sample text messages that apply personalized content will be created to enhance medication adherence. We found that education alone increased medication adherence in prior studies, so we will deliver cardiovascular risk reduction messages along with messages regarding medications. Topics will include medications, diet, exercise, risk factors for coronary heart disease (eg, smoking, obesity), depression, stress management, and preventive care. Participants will choose the frequency and timing of text messaging. An example of an automated medication text messaging may be, &#x0201c;John, take your Plavix 75mg at 9am. Confirm with 1.&#x0201d;</p></sec><sec><title>Recruitment</title><p>We will distribute written materials such as flyers and brochures to advertise voluntary participation in the research study. The research team (principal investigator and research assistant [RA]) will consult with the cardiac rehabilitation staff at SFVAMC and JMMC to identify individuals who are willing to participate in a research study. The research team will meet with interested individuals and provide verbal and written explanation of the study. Participants will sign a written informed consent document.</p></sec><sec><title>Group Assignment</title><p>Upon recruitment into the study, participants will complete a sociodemographic questionnaire and a brief survey that will determine if he/she is a <italic>low</italic> or <italic>high</italic> mobile phone user. Separating participants into groups will help facilitate identification of common ideas and goals that low/high mobile phone users and men/women may address during the focus groups. We will use maximum variation sampling to ensure variability in age, gender, ethnicity, and low/high mobile phone use.</p></sec><sec><title>Focus Groups</title><p>In Aim 1, the focus group sessions will address ideal content and frequency of text messaging. First, we will give an introduction of the study aims and purpose of the focus group. Second, we will discuss the needs, preferences, perceived facilitators, and perceived barriers of using text messaging for medication adherence. Third, we will review sample text messaging, and we will ask participants which content and frequency of text messaging are the most effective and least intrusive. Finally, all participants will be able to suggest text messaging to create the most personalized messages.</p></sec><sec><title>Data Collection</title><p>All focus groups will be audiotaped, and the RA will take field notes on individual and group reactions that are not captured by the recording. We will complete field notes at the conclusion of each session, and all sessions will be transcribed verbatim.</p></sec></sec><sec><title>Analysis</title><p>Thematic analysis will include reading and coding the completed field notes and interview transcripts. We will create an initial set of codes that account for the study aims and other topics that emerge from the data. Some codes will be generated deductively, while others will be generated inductively based on themes and issues that emerge from ongoing coding. We will compare coding, resolve differences, and revise the coding scheme. We will assess intercoder reliability by having 10% of the data cross-coded. The key outcomes will be content and frequency of text messaging, particularly focusing on how preferences vary across groups. We will use ATLAS.ti (Thousand Oaks, CA) for all qualitative analyses to determine the preferred app for Aim 3.</p></sec></sec><sec><title>Aim 2: Mobile Apps: Focus Groups</title><sec><title>Design, Sample, and Setting</title><p>Aim 2 consists of Aim 2a (<italic>content analysis</italic>) and Aim 2b (<italic>usability testing</italic>). The usability study will include the same individuals from the focus groups in Aim 1 who are stratified by low/high mobile phone use and sex, to accommodate easy exchanges of ideas and a diversity of perspectives. In contrast to Aim 1, there will be three focus group sessions to fulfill Aim 2. Recruitment, group assignment, and data collection will be the same for Aim 2a and Aim 2b.</p><sec><title>Aim 2a &#x02013; Content Analysis</title><sec><title>Methods</title><p>We will conduct a content analysis approximately three months prior to the focus groups. The first phase will involve a comparative, descriptive assessment of smartphone apps in the categories of health and medications. To ensure a comprehensive search, the research team will search for medication adherence-oriented apps, provider websites, and app sources that are available in Apple iTunes, Android Marketplace, and Blackberry App World Store.</p><p>We will provide a comparative, descriptive assessment of the top 10 smartphone apps related to medication adherence. The content analysis will examine whether each app applies constructs from behavioral change theory. We will assess each of the selected apps using a validated behavioral theory content survey by Doshi et al [<xref rid="ref35" ref-type="bibr">35</xref>]. The survey assesses the presence of essential constructs of four major theories of behavior change: Health Belief Model, Transtheoretical Model, Theory of Reasoned Action/Planned Behavior, and Social Cognitive/Social Learning Theory [<xref rid="ref35" ref-type="bibr">35</xref>]. After content analysis is completed, we will rank the top 10 medication adherence apps and record usability, application of theory, user reviews, star ratings, and the total number of downloads.</p></sec><sec><title>Analyses</title><p>We will analyze the content analysis by following the scoring instructions of the Behavioral Theory Content Survey for the top 10 mobile apps [<xref rid="ref35" ref-type="bibr">35</xref>]. The Behavioral Theory Content Survey will include 20 items from the following domains listed in <xref ref-type="table" rid="table1">Table 1</xref>. Mean survey score and standard deviation (SD) will be computed across the top 10 apps based on a total of 20 items from the 5 domains, each accounting for 1 point (yes=1, no=2) [<xref rid="ref35" ref-type="bibr">35</xref>]. We will then provide a descriptive evaluation of the apps based primarily on survey scores (mean, SD) and subsequent rankings [<xref rid="ref36" ref-type="bibr">36</xref>]. Interacting with the mobile app will include a dynamic process of iterative adjustments in response to user input, key features, and functionality that may not be apparent upon initial use and subsequent input [<xref rid="ref36" ref-type="bibr">36</xref>].</p><table-wrap id="table1" position="float"><label>Table 1</label><caption><p>Behavioral strategies included in the Behavioral Theory Content Survey [<xref rid="ref35" ref-type="bibr">35</xref>,<xref rid="ref36" ref-type="bibr">36</xref>].</p></caption><table frame="hsides" rules="groups" width="623" cellpadding="7" cellspacing="0" border="1"><col width="202" span="1"/><col width="391" span="1"/><thead><tr valign="top"><td rowspan="1" colspan="1">Domain</td><td rowspan="1" colspan="1">Example</td></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">1. Knowledge</td><td rowspan="1" colspan="1">General information</td></tr><tr valign="top"><td rowspan="1" colspan="1">2. Cognitive strategies</td><td rowspan="1" colspan="1">Perceived benefits/barriers/risks, self-efficacy</td></tr><tr valign="top"><td rowspan="1" colspan="1">3. Behavioral strategies</td><td rowspan="1" colspan="1">Self-monitoring, time management, social support</td></tr><tr valign="top"><td rowspan="1" colspan="1">4. Emotion-focused strategies</td><td rowspan="1" colspan="1">Stress management</td></tr><tr valign="top"><td rowspan="1" colspan="1">5. Therapeutic interventions</td><td rowspan="1" colspan="1">Motivational readiness</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Aim 2b - Usability Testing: Methods</title><sec><title>Mobile App Focus Groups &#x02013; Session 1 (Formative Stage)</title><p>After the research team identifies the top 10 medication reminder apps through content analyses, the focus group for Session 1 will help to determine the top 2-4 apps the participants will use for one week at a time. Four different groups will be stratified by low/high mobile phone use and sex (<xref ref-type="fig" rid="figure3">Figure 3</xref>). We will briefly demonstrate the apps for participants on a large screen and ask participants to engage with the preloaded apps on our research smartphones. We will assess participants&#x02019; impressions of the apps and ask them to score the apps (range 1-5) so we can determine the ideal number of apps to trial from the distribution of rankings. Participants&#x02019; comments and overall scores will help determine the preferred apps.</p></sec><sec><title>Session 2 (Exploratory Stage)</title><p>During the focus group for Session 2, the majority of time will be spent on group assessment of overall experience with mobile apps in general. After the group assessment, we will include introduction of the preselected apps from Session 1. The selected apps from Session 1 will be downloaded to the patients&#x02019; mobile phones devices. Patients will spend approximately 10-15 minutes experimenting with and evaluating the selected apps. We will conduct observations of patients as they interact with the mobile apps. Participants will be randomly assigned to use the first app in Session 2 and use that app for one week, then switch to the other app(s) in subsequent weeks. <xref ref-type="fig" rid="figure3">Figure 3</xref> displays a scenario in which participants will be randomly assigned to use two mobile apps for two weeks; however, participants may trial between 2-4 mobile apps for one week each, depending on the results of the Mobile App Session 1 focus groups.</p><p>Participants will record impressions in a diary while using the apps. We will contact the participants by text/email/ phone-call/visit within two days after using each mobile app to troubleshoot any difficulties. At the start of each week, we will contact participants to remind them to switch over to the next mobile app.</p></sec><sec><title>Session 3 (Usability Stage)</title><p>After the trial period with mobile apps, the focus group for Session 3 (which assesses usability) will include: (1) follow-up on patients&#x02019; experience and preferences with using the selected mobile apps, and (2) completion of a 10-item System Usability Scale to provide a quantitative evaluation of the mobile apps to supplement the focus groups and interviews [<xref rid="ref37" ref-type="bibr">37</xref>]. A winning app will be selected for the RCT.</p></sec></sec><sec><title>Usability Testing: Analysis</title><p>The three focus group sessions for Aim 2 will be transcribed, coded, and analyzed in the same manner as in Aim 1. The System Usability Scale used in the Mobile App Session 3 focus group will yield a single number from 0 to 100 representing a composite measure of the overall usability of mobile apps being tested [<xref rid="ref37" ref-type="bibr">37</xref>]. The scale will be scored as directed by the original authors.</p></sec></sec></sec><sec><title>Aim 3: Medication Adherence Randomized Controlled Trial</title><sec><title>Design</title><p>The research design for Aim 3 is an RCT that lasts 12 months. In contrast to Aims 1 and 2 that included participants who were post-ACS/PCI within one year and recruited from a cardiac rehabilitation program, participants for Aim 3 will be recruited from the hospital after ACS/PCI.</p></sec><sec><title>Sample Size Estimation</title><p>We plan to enroll 225 total participants (75 participants per group). Allowing for a 15% attrition rate over the 12-month study, we conservatively estimate that this recruitment target will result in a total sample size of n=192, which will give 86% power to detect a medium effect size (half-SD difference) between at least one treatment group and the control group using Dunnett&#x02019;s method to adjust for multiple comparisons. This sample size would give more than 95% power to detect an effect size of d=0.69, as found in our previous clinical trial [<xref rid="ref33" ref-type="bibr">33</xref>]. Analysis of the longitudinal data points with mixed-effects models will confer additional power.</p></sec><sec><title>Sample</title><p>The convenience sample will consist of 159 male and female Veterans from SFVAMC and 66 female participants (29% of sample) from JMMC. A sample size of 225 is considered to be feasible considering the number of post-ACS/PCI patients who are treated at both institutions. We have incorporated a 29% oversample of women to ensure a sufficient sample size to examine subgroup differences in intervention effects, given the low enrollment of female Veterans in Veterans Health Administration (6%) [<xref rid="ref38" ref-type="bibr">38</xref>]. Inclusion criteria include: (1) &#x0003e;21 years of age, (2) recent ACS or PCI within one week, and (3) new antiplatelet (thienopyridine) prescription. Exclusion criteria are: (1) cognitive impairment, and (2) lack of English proficiency/literacy. For the process evaluation, we will recruit a subset of 10 participants from each experimental group (text messaging and mobile app; total n=20) for in-depth individual interviews.</p></sec><sec><title>Settings and Recruitment</title><p>We will recruit from SFVAMC and JMMC inpatient units using two recruitment strategies. First, we will inform the cardiologists and nurses in the cardiac units at the hospital sites about the study so they can identify patients who meet eligibility criteria. A patient-friendly handout will be made available for the health care team to give to interested participants. Second, we will obtain a daily list of patients who had PCI and their electronic medical records will be screened for eligibility in the study using a checklist to examine the inclusion and exclusion criteria. Participants who agree to participate will provide written informed consent.</p></sec><sec><title>Randomization</title><p>Group assignment will be generated by random allocation sequence using random blocks stratified within recruitment site (SFVAMC or JMMC) of either three or six, which will be prepared by the study biostatistician. The research team will assign patients to their groups by distributing presealed envelopes in consecutive, numbered order. Due to the nature of the study design, the research team and participants cannot be blinded to the intervention once group assignment is determined.</p></sec><sec><title>Baseline Data Collection</title><p>After written consent is obtained, we will collect clinical data by reviewing electronic medical records. Participants will complete the following baseline questionnaires: (1) sociodemographic information and medical history, (2) mobile phone use, and (3) Mini-Cog Test [<xref rid="ref39" ref-type="bibr">39</xref>]. All instruments and frequency of administration are described in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" position="float"><label>Table 2</label><caption><p>Measurement of medication adherence with intervals.</p></caption><table frame="hsides" rules="groups" width="623" cellpadding="7" cellspacing="0" border="1"><col width="100" span="1"/><col width="190" span="1"/><col width="100" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><thead><tr valign="top"><td rowspan="1" colspan="1">Measure</td><td rowspan="1" colspan="1">Description</td><td rowspan="1" colspan="1">Rationale</td><td colspan="6" rowspan="1">Months</td></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">12</td></tr><tr valign="top"><td colspan="9" rowspan="1">Key Primary Endpoint</td></tr><tr valign="top"><td rowspan="1" colspan="1">Medication Event Monitoring System (MEMS) [<xref rid="ref40" ref-type="bibr">40</xref>]</td><td rowspan="1" colspan="1">Electronic pill caps time stamp when the bottle is opened, correlating with intake of medication. Primary outcome is percentage (0-100%) of prescribed doses taken</td><td rowspan="1" colspan="1">Most objective, noninvasive method and considered the &#x0201c;gold standard&#x0201d;</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td colspan="9" rowspan="1">Secondary Patient-Reported Endpoints</td></tr><tr valign="top"><td rowspan="1" colspan="1">MEMS [<xref rid="ref40" ref-type="bibr">40</xref>]</td><td rowspan="1" colspan="1">Percentages (0-100%) of (1) days correct doses are taken, and (2) doses taken on schedule</td><td rowspan="1" colspan="1">Most objective, noninvasive method and considered the &#x0201c;gold standard&#x0201d;</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">Morisky Scale [<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref42" ref-type="bibr">42</xref>]</td><td rowspan="1" colspan="1">Eight-item Morisky Medication Adherence Scale (MMAS-8) self-reported questionnaire on adherence behavior for a range of scores 0-8, with higher scores indicating poor adherence (Cronbach alpha=0.83).</td><td rowspan="1" colspan="1">Most popular scale and well-validated instrument with high reliability</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">7-Day Recall</td><td rowspan="1" colspan="1">One item asking how many days in the past week patient remembered to take medications. Final outcome is a percentage (0-100%).</td><td rowspan="1" colspan="1">Most commonly used method in the clinical setting</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td colspan="9" rowspan="1">Secondary Objective Endpoints</td></tr><tr valign="top"><td rowspan="1" colspan="1">Veterans Affairs Corporate Data Warehouse (Veterans)</td><td rowspan="1" colspan="1">Veterans Affairs software program that provides detailed information on inpatient and outpatient medications. Final outcome is a percentage (0-100%) of days covered during 90-day period.</td><td rowspan="1" colspan="1">Assesses adherence via 90-day refill patterns (does not require active participation)</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">Peoplechart Meds Incontext (non-Veterans)</td><td rowspan="1" colspan="1">Private software program that uses refill data directly from retail pharmacies and Personal Benefits Manager. Final outcome is a percentage (0-100%) of days covered during 90-day period.</td><td rowspan="1" colspan="1">Assesses adherence via monthly refill patterns (does not require active participation)</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td></tr></tbody></table></table-wrap></sec><sec><title>Intervention</title><p>We will conduct an RCT with random assignment to one of three groups: (1) text messaging, (2) mobile app, or (3) website-control, for a total of 12 months. Both intervention groups will also be offered the patient education website that the control group will be given. The <italic>text messaging group</italic> will receive text messages with content and frequency informed by Aim 1. We will use the Veterans Affairs (VA) <italic>Annie</italic> text messaging program. For non-Veteran females, we will use a text messaging program from CareSpeak Communications. The <italic>app group</italic> will use the preferred app that is selected in Aim 2. The major purpose of the app is to remind participants to take medications; however, the app will likely include other features such as providing educational messages. The <italic>website group</italic> will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an active control group [<xref rid="ref43" ref-type="bibr">43</xref>]. The website will be offered to participants in all three groups. The <italic>7 small steps to big changes</italic> are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking.</p></sec><sec><title>Follow-Up Visits</title><p>Subsequent in-person follow-up visits at 1, 6, and 12 months will take place in participants&#x02019; homes or other mutual meeting places as requested. Follow-up visits will be scheduled at times that are convenient for participants to meet.</p></sec></sec><sec><title>Primary Outcome/Other Variables and Instruments</title><sec><title>Primary Outcome: Medication Adherence</title><p>Medication adherence will be assessed with five different measures at various intervals to validate patterns of adherence, including: Medication Event Monitoring System (MEMS; key primary endpoint being percentage of prescribed doses taken), Morisky Medication Adherence Scale (MMAS-8), 7-day recall, VA Corporate Data Warehouse (Veterans), and Peoplechart Meds Incontext (non-Veterans; <xref ref-type="table" rid="table2">Table 2</xref>). In-person follow-up visits will occur at 1, 6, and 12 months, while monitoring of adherence through refill data from computer software will be done monthly to reduce participant burden.</p><p>MEMS technology uses integrated microcircuits with bottle caps that record the date and time that an individual opens a pill bottle. Participants will be given one bottle to store their antiplatelet medication, and will be directed to store their other medications as they normally would. For those who use 7-day pill boxes, we will emphasize the need to use the MEMS bottle for the antiplatelet medication. Data will be wirelessly transferred to a MEMSCap reader, which is a small device that connects to a computer software program.</p><p>Refill data from computer software will also allow us to monitor prescription adherence passively, without requiring patient participation. We will use administrative data from the national VA repository (VA Corporate Data Warehouse) to provide adherence to antiplatelet medication for Veterans. For non-Veteran females from JMMC, we will use an equivalent data source through Peoplechart Meds Incontext, which is a software program that tracks adherence through sanctioned prescription data sourced directly from retail pharmacies and Prescription Benefits Managers (ie, mail-order companies).</p></sec><sec><title>Other Variables and Instruments</title><p>We will examine other variables (health-related quality of life, social support, self-efficacy, depression, anxiety, and post-traumatic stress disorder) and their relationship to medication adherence. Patients will complete the instruments at baseline, 1, 6, and 12 months (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" position="float"><label>Table 3</label><caption><p>Instruments used to assess additional variables.</p></caption><table frame="hsides" rules="groups" width="623" cellpadding="7" cellspacing="0" border="1"><col width="65" span="1"/><col width="350" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><col width="15" span="1"/><thead><tr valign="top"><td rowspan="1" colspan="1">Measure</td><td rowspan="1" colspan="1">Description</td><td colspan="6" rowspan="1">Months</td></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">12</td></tr><tr valign="top"><td rowspan="1" colspan="1">Health-related quality of life</td><td rowspan="1" colspan="1">The 12-Item Short Form Health Survey (SF-12) is the shorter version of SF-36, which measures functional health and well-being (relative validity median 0.67 and 0.97 for the physical and mental components, respectively) [<xref rid="ref44" ref-type="bibr">44</xref>].</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">Social support</td><td rowspan="1" colspan="1">The 20-item Medical Outcomes Study Social Support Survey Instrument uses multi-trait scaling analyses of 4 functional support scales and provides an overall functional social support index (Cronbach alpha=0.91) [<xref rid="ref45" ref-type="bibr">45</xref>].</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">Medication self-efficacy</td><td rowspan="1" colspan="1">The 13-item Self-Efficacy for Appropriate Medication Use Scale measures how confident individuals are in taking their medications correctly in certain situations (Cronbach alpha=0.89) [<xref rid="ref46" ref-type="bibr">46</xref>].</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">Depression</td><td rowspan="1" colspan="1">The 9-item Patient Health Questionnaire is used to diagnose and measure the severity of depression as well as monitor response to treatment (Cronbach alpha=0.89) [<xref rid="ref47" ref-type="bibr">47</xref>].</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">Anxiety</td><td rowspan="1" colspan="1">The 7-item Generalized Anxiety Disorder Assessment is used to screen and measure severity of generalized anxiety disorder (Cronbach alpha=0.92) [<xref rid="ref48" ref-type="bibr">48</xref>].</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr><tr valign="top"><td rowspan="1" colspan="1">Post-traumatic stress disorder</td><td rowspan="1" colspan="1">The 17-item Post-Traumatic Stress Disorder Checklist: Civilian is a popular self-report rating scale for post-traumatic stress disorder. The civilian version will be used instead of the military version because the majority of participants will not have been on recent active duty, &#x0003e;35% of Veterans with post-traumatic stress disorder had a nonmilitary trauma, and non-Veteran women will be included (29%; Cronbach alpha=0.87) [<xref rid="ref49" ref-type="bibr">49</xref>].</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td><td rowspan="1" colspan="1"><break/></td><td rowspan="1" colspan="1">x</td></tr></tbody></table></table-wrap></sec><sec><title>Process Evaluation</title><p>Upon completion of the intervention study, we will conduct a process evaluation so that improvements can be made for a multi-site full scale study. The objectives of the process evaluation are to assess participants&#x02019; perspectives on feasibility, acceptability, usability, challenges, strengths, and weaknesses of the intervention. In addition, we will ascertain reasons for nonadherence to antiplatelet medications since understanding the reasons for nonadherence is crucial to avoid negative patient outcomes. We will adopt a qualitative research approach using in-depth individual interviews from a diverse sample of participants (total n=20).</p></sec><sec><title>Analysis</title><p>Descriptive statistics, means, and SDs for quantitative variables, and frequencies and percentages for categorical variables, will be provided for all demographic and study variables. Random assignment of the patients to the text messaging, mobile app, and website groups should ensure that there are no preexisting differences between the three groups in personal factors (eg, sociodemographic, clinical, and psychosocial characteristics).</p></sec><sec><title>Medication Adherence</title><p>The primary outcome will be the percentage of prescribed doses taken based on MEMS data (aggregated over 12 months). Secondary outcomes will include: (1) percentages of days correct number of doses were taken, (2) doses taken on schedule, (3) MMAS-8, (4) 7-day recall, (5) VA Corporate Data Warehouse (Veterans), and (6) Peoplechart Meds Incontext (non-Veterans). The MMAS-8 will be analyzed as a range of 0-8. We will synthesize adherence measures with the key primary endpoint of MEMS data compared with secondary measures of adherence to assess for concurrent and predictive validity. We will also calculate associations between all of the adherence measures but expect that they will track well together. Prior to fitting the mixed-effects linear model, we will examine univariate and bivariate relationships between the outcomes and both demographic and coded qualitative responses.</p></sec><sec><title>Primary Statistical Analysis</title><p>Our primary analysis will use a mixed-effects linear model. The predictors will be a categorical predictor of group (with control as reference), time, and the group-by-time interactions, as well as the recruitment site (SFVAMC vs JMMC), as randomization is stratified by site. The parameters in the group-by-time interaction are the primary parameters of interest, describing whether adherence changes differentially over baseline in each of the treatment groups compared to the control group. We will also investigate whether other models for change over time are more appropriate, including arbitrary means or nonlinear time functions through comparison of Akaike information criterion/Bayesian information criterion. Secondary analyses will adjust for select covariates that are strongly associated with adherence.</p></sec><sec><title>Predictors of Medication Adherence</title><p>To determine the factors related to medication adherence, we will examine sociodemographic, clinical, and psychosocial variables. The variables that show at least a moderate correlation and have a significant relationship to medication adherence (<italic>P</italic>&#x0003c;0.10) will be included in a multiple regression analysis in which medication adherence is the dependent variable. The multiple regression analysis will provide the optimum combination of these variables to explain the total percent of variance in medication adherence, and indicate the unique contribution of each variable to the regression model.</p></sec><sec><title>Process Evaluation</title><p>The in-depth individual interviews for process evaluation will be transcribed, coded, and analyzed in the same manner as in Aims 1 and 2. We will explore reasons for attrition over the 12-month period. We will complete field notes after the conclusion of each interview, and all interviews will be transcribed verbatim. Thematic analysis will include reading the completed field notes and interview transcripts. The key outcomes will be related to patient satisfaction and process evaluation, particularly focusing on how views vary across groups.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><p>We began enrollment for the Mobile4Meds focus groups in January 2017. The focus group data will inform the development of the RCT, which is scheduled to begin in early 2018. We anticipate this four-year research study will be completed in late 2020.</p><p>We believe that participants will provide valuable contributions on the content and frequency of text messaging in Aim 1. We expect that focus groups that are stratified by low/high mobile phone use and sex will have differing opinions on frequency of text messaging delivery; however, we also predict that the perceived usefulness of text messaging content will be similar across groups. Based on participants&#x02019; responses, we will refine our text messaging content and frequency in preparation for Aim 3.</p><p>By conducting Aim 2, we will complete a content analysis of the top 10 commercially available mobile apps that will provide an evidence-based guide for health researchers and clinicians. We expect that using the top 2-4 selected mobile apps over 2-4 weeks on participants&#x02019; personal smartphones will provide clear insight into which mobile app should be used for the RCT.</p><p>This study is powered to prove the efficacy of using different mobile strategies to promote adherence to antiplatelet medications. By conducting Aim 3, we will compare two mHealth strategies (with a website-control condition) among Veterans using multiple methods to assess adherence. We will also examine the relationship between medication adherence and important variables (ie, health-related quality of life, social support, self-efficacy, depression, anxiety, and post-traumatic stress disorder). The study duration of 12 months, which is the recommended duration of antiplatelet use for most MI/PCI patients, will provide valuable information about patterns of medication adherence.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Evaluating the clinical application of mHealth strategies through rigorous scientific design and methodology is an important step in establishing whether there is potential for long-term benefit among Veterans who live with chronic disease [<xref rid="ref50" ref-type="bibr">50</xref>]. The best way to ensure strict medication adherence in patients has continued to elude health care providers. Worldwide development and adoption of mobile technology has successfully spurred dramatic growth of mHealth as a platform to deliver intervention strategies for various health conditions in the past several years [<xref rid="ref51" ref-type="bibr">51</xref>].</p><p>Researchers suggest that patient knowledge, self-monitoring, counseling, accountability, and a personalized program can contribute to improvement in medication adherence [<xref rid="ref52" ref-type="bibr">52</xref>]. Experts and multiple stakeholders in medication adherence agree that a patient-centered approach is necessary, and increasing patient knowledge is critically important [<xref rid="ref25" ref-type="bibr">25</xref>]. Technological solutions have been suggested to alleviate medication nonadherence, such as mHealth technology, electronic monitors, pill-monitoring technology, online resources, and social media [<xref rid="ref52" ref-type="bibr">52</xref>]. The best manner to engage with Veterans via text messaging and mobile apps has yet to be determined among those of different ages, sexes, chronic diseases, mobile phone usage patterns, and ethnic populations. There are many opportunities to explore these unanswered questions in future studies.</p><sec><title>Limitations</title><p>There are potential limitations associated with this study. In Aims 1 and 2, if we do not reach saturation of ideas or if we find distinct differences between groups, we may add a mixed-group to tease out differences. We may also add an additional focus group of mixed and unstratified participants to identify differences. Alternatively, we will conduct structured one-on-one interviews to acquire richer information as a supplement to the focus groups.</p><p>In Aim 3, a limitation may be attrition due to Veteran disinterest in receiving text messages or using a mobile app for 12 months. We will address the potential barrier of disinterest during the two focus groups, as planned in Aims 1 and 2, and ask Veterans how to best engage with them after ACS/PCI over 12 months. Multiple strategies will be used to maximize participant retention and decrease missing data, since the intervention is intended to last 12 months. The dropout or missing data rates for the three groups will be examined to see that they are significantly different. Sensitivity analyses will include a complete-case analysis.</p><p>Another potential limitation may be cross-over effects for the text messaging and website (control) groups if they use a mobile app concurrently during the RCT. We will request that patients not use any other electronic medication reminders, including on their mobile phones (eg, alarm, app). At the conclusion of the study, we will ask participants in the text messaging and control groups if they used any other electronic reminders. If they have, we will conduct sensitivity analyses as described.</p></sec><sec><title>Conclusions</title><p>As the aims of Mobile4Meds are achieved, scientific knowledge and clinical implementation of behavioral change interventions related to mobile technology and medication adherence will be advanced. Improving medication adherence through mHealth technology may have significant effects on lowering morbidity and mortality among Veterans with coronary heart disease. Since poor adherence to long-term therapies severely compromises the effectiveness of treatment, providing innovative solutions through mHealth may provide relief for this critical issue in population health from the perspective of clinical outcomes and quality of life [<xref rid="ref53" ref-type="bibr">53</xref>]. Moreover, since medication nonadherence is a major global problem [<xref rid="ref1" ref-type="bibr">1</xref>], using mHealth strategies may be a powerful solution to reach large, diverse populations in a cost-effective manner. In the future, implementing a strategy to promote adherence through the vulnerable period of 12 months post-ACS/PCI may be highly acceptable and generalizable. The findings from Mobile4Meds may also be highly applicable to other patient classes who require long-term treatment and strict medication adherence.</p></sec></sec></body><back><ack><p>Dr. Park is supported by the Department of Veterans Affairs Health Services Research and Development Nursing Research Initiative Award (1 IK3 HX002055-01A1). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2TR001870. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. This project was also supported by the University of California, San Francisco Clinical and Translational Science Institute (UL1 TR000004).</p></ack><fn-group><fn fn-type="COI-statement"><p>Conflicts of Interest: None declared.</p></fn></fn-group><app-group><app id="app1"><title>Multimedia Appendix 1</title><p>This is the peer-review summary statement for the grant proposal association with this manuscript. The recommended changes were applied to the final grant proposal that was funded.</p><fig id="d35e1234" position="anchor"><media xlink:href="resprot_v6i7e134_app1.pdf"/></fig></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">ACS</term><def><p>acute coronary syndrome</p></def></def-item><def-item><term id="abb2">JMMC</term><def><p>John Muir Medical Center</p></def></def-item><def-item><term id="abb3">MEMS</term><def><p>Medication Event Monitoring System</p></def></def-item><def-item><term id="abb4">mHealth</term><def><p>mobile health</p></def></def-item><def-item><term id="abb5">MI</term><def><p>myocardial infarction</p></def></def-item><def-item><term id="abb6">MMAS-8</term><def><p>Morisky Medication Adherence Scale</p></def></def-item><def-item><term id="abb7">PCI</term><def><p>percutaneous coronary intervention</p></def></def-item><def-item><term id="abb8">RA</term><def><p>research assistant</p></def></def-item><def-item><term id="abb9">RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term id="abb10">SD</term><def><p>standard deviation</p></def></def-item><def-item><term id="abb11">SFVAMC</term><def><p>San Francisco Veterans Affairs Medical Center</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Boerma</surname><given-names>T</given-names></name><name><surname>Ma Fat</surname><given-names>D</given-names></name></person-group><source>The Global Burden of Disease: 2004 Update</source><year>2008</year><date-in-citation>2013-03-28</date-in-citation><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1">http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1</ext-link><ext-link ext-link-type="webcite" xlink:href="9789241563710"/></comment></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>de Ferranti</surname><given-names>S</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Fullerton</surname><given-names>HJ</given-names></name><name><surname>Howard</surname><given-names>VJ</given-names></name><name><surname>Huffman</surname><given-names>MD</given-names></name><name><surname>Judd</surname><given-names>SE</given-names></name><name><surname>Kissela</surname><given-names>BM</given-names></name><name><surname>Lackland</surname><given-names>DT</given-names></name><name><surname>Lichtman</surname><given-names>JH</given-names></name><name><surname>Lisabeth</surname><given-names>LD</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Mackey</surname><given-names>RH</given-names></name><name><surname>Matchar</surname><given-names>DB</given-names></name><name><surname>McGuire</surname><given-names>DK</given-names></name><name><surname>Mohler</surname><given-names>ER</given-names></name><name><surname>Moy</surname><given-names>CS</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Mussolino</surname><given-names>ME</given-names></name><name><surname>Nasir</surname><given-names>K</given-names></name><name><surname>Neumar</surname><given-names>RW</given-names></name><name><surname>Nichol</surname><given-names>G</given-names></name><name><surname>Palaniappan</surname><given-names>L</given-names></name><name><surname>Pandey</surname><given-names>DK</given-names></name><name><surname>Reeves</surname><given-names>MJ</given-names></name><name><surname>Rodriguez</surname><given-names>CJ</given-names></name><name><surname>Sorlie</surname><given-names>PD</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Towfighi</surname><given-names>A</given-names></name><name><surname>Turan</surname><given-names>TN</given-names></name><name><surname>Virani</surname><given-names>SS</given-names></name><name><surname>Willey</surname><given-names>JZ</given-names></name><name><surname>Woo</surname><given-names>D</given-names></name><name><surname>Yeh</surname><given-names>RW</given-names></name><name><surname>Turner</surname><given-names>MB</given-names></name><collab>American Heart Association Statistics Committee and Stroke Statistics Subcommittee</collab></person-group><article-title>Heart disease and stroke statistics--2015 update: a report from the American Heart Association</article-title><source>Circulation</source><year>2015</year><month>1</month><day>27</day><volume>131</volume><issue>4</issue><fpage>e29</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000152</pub-id><pub-id pub-id-type="medline">25520374</pub-id><!--<pub-id pub-id-type="pii">CIR.0000000000000152</pub-id>--><pub-id pub-id-type="pmid">25520374</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pursnani</surname><given-names>S</given-names></name><name><surname>Korley</surname><given-names>F</given-names></name><name><surname>Gopaul</surname><given-names>R</given-names></name><name><surname>Kanade</surname><given-names>P</given-names></name><name><surname>Chandra</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>RE</given-names></name><name><surname>Bangalore</surname><given-names>S</given-names></name></person-group><article-title>Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials</article-title><source>Circ Cardiovasc Interv</source><year>2012</year><month>8</month><day>01</day><volume>5</volume><issue>4</issue><fpage>476</fpage><lpage>90</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://circinterventions.ahajournals.org/cgi/pmidlookup?view=long&#x00026;pmid=22872053"/></comment><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.112.970954</pub-id><pub-id pub-id-type="medline">22872053</pub-id><!--<pub-id pub-id-type="pii">CIRCINTERVENTIONS.112.970954</pub-id>--><pub-id pub-id-type="pmid">22872053</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stergiopoulos</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>DL</given-names></name></person-group><article-title>Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials</article-title><source>Arch Intern Med</source><year>2012</year><month>2</month><day>27</day><volume>172</volume><issue>4</issue><fpage>312</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2011.1484</pub-id><pub-id pub-id-type="medline">22371919</pub-id><!--<pub-id pub-id-type="pii">172/4/312</pub-id>--><pub-id pub-id-type="pmid">22371919</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Ajani</surname><given-names>UA</given-names></name><name><surname>Croft</surname><given-names>JB</given-names></name><name><surname>Critchley</surname><given-names>JA</given-names></name><name><surname>Labarthe</surname><given-names>DR</given-names></name><name><surname>Kottke</surname><given-names>TE</given-names></name><name><surname>Giles</surname><given-names>WH</given-names></name><name><surname>Capewell</surname><given-names>S</given-names></name></person-group><article-title>Explaining the decrease in U.S. deaths from coronary disease, 1980-2000</article-title><source>N Engl J Med</source><year>2007</year><month>6</month><day>07</day><volume>356</volume><issue>23</issue><fpage>2388</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1056/NEJMsa053935</pub-id><pub-id pub-id-type="medline">17554120</pub-id><!--<pub-id pub-id-type="pii">356/23/2388</pub-id>--><pub-id pub-id-type="pmid">17554120</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Morden</surname><given-names>NE</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Malenka</surname><given-names>DJ</given-names></name><name><surname>Skinner</surname><given-names>J</given-names></name></person-group><article-title>Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2012</year><month>1</month><volume>5</volume><issue>1</issue><fpage>103</fpage><lpage>12</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://circoutcomes.ahajournals.org/cgi/pmidlookup?view=long&#x00026;pmid=22147885"/></comment><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.111.962704</pub-id><pub-id pub-id-type="medline">22147885</pub-id><!--<pub-id pub-id-type="pii">CIRCOUTCOMES.111.962704</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3261311</pub-id>--><pub-id pub-id-type="pmid">22147885</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossini</surname><given-names>R</given-names></name><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Lettieri</surname><given-names>C</given-names></name><name><surname>Musumeci</surname><given-names>G</given-names></name><name><surname>Nijaradze</surname><given-names>T</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Lortkipanidze</surname><given-names>N</given-names></name><name><surname>Cicorella</surname><given-names>N</given-names></name><name><surname>Biondi</surname><given-names>ZG</given-names></name><name><surname>Sirbu</surname><given-names>V</given-names></name><name><surname>Izzo</surname><given-names>A</given-names></name><name><surname>Guagliumi</surname><given-names>G</given-names></name><name><surname>Valsecchi</surname><given-names>O</given-names></name><name><surname>Gavazzi</surname><given-names>A</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name></person-group><article-title>Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation</article-title><source>Am J Cardiol</source><year>2011</year><month>1</month><day>15</day><volume>107</volume><issue>2</issue><fpage>186</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2010.08.067</pub-id><pub-id pub-id-type="medline">21211596</pub-id><!--<pub-id pub-id-type="pii">S0002-9149(10)01856-4</pub-id>--><pub-id pub-id-type="pmid">21211596</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spertus</surname><given-names>JA</given-names></name><name><surname>Kettelkamp</surname><given-names>R</given-names></name><name><surname>Vance</surname><given-names>C</given-names></name><name><surname>Decker</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>PG</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name><name><surname>Messenger</surname><given-names>JC</given-names></name><name><surname>Khanal</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Bach</surname><given-names>RG</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Cohen</surname><given-names>DJ</given-names></name></person-group><article-title>Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry</article-title><source>Circulation</source><year>2006</year><month>6</month><day>20</day><volume>113</volume><issue>24</issue><fpage>2803</fpage><lpage>9</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://circ.ahajournals.org/cgi/pmidlookup?view=long&#x00026;pmid=16769908"/></comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.618066</pub-id><pub-id pub-id-type="medline">16769908</pub-id><!--<pub-id pub-id-type="pii">CIRCULATIONAHA.106.618066</pub-id>--><pub-id pub-id-type="pmid">16769908</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Airoldi</surname><given-names>F</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Morici</surname><given-names>N</given-names></name><name><surname>Latib</surname><given-names>A</given-names></name><name><surname>Cosgrave</surname><given-names>J</given-names></name><name><surname>Buellesfeld</surname><given-names>L</given-names></name><name><surname>Bonizzoni</surname><given-names>E</given-names></name><name><surname>Carlino</surname><given-names>M</given-names></name><name><surname>Gerckens</surname><given-names>U</given-names></name><name><surname>Godino</surname><given-names>C</given-names></name><name><surname>Melzi</surname><given-names>G</given-names></name><name><surname>Michev</surname><given-names>I</given-names></name><name><surname>Montorfano</surname><given-names>M</given-names></name><name><surname>Sangiorgi</surname><given-names>GM</given-names></name><name><surname>Qasim</surname><given-names>A</given-names></name><name><surname>Chieffo</surname><given-names>A</given-names></name><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Grube</surname><given-names>E</given-names></name></person-group><article-title>Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment</article-title><source>Circulation</source><year>2007</year><month>8</month><day>14</day><volume>116</volume><issue>7</issue><fpage>745</fpage><lpage>54</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://circ.ahajournals.org/cgi/pmidlookup?view=long&#x00026;pmid=17664375"/></comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.686048</pub-id><pub-id pub-id-type="medline">17664375</pub-id><!--<pub-id pub-id-type="pii">CIRCULATIONAHA.106.686048</pub-id>--><pub-id pub-id-type="pmid">17664375</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>DT</given-names></name><name><surname>Chiu</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Marquis</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>JV</given-names></name></person-group><article-title>Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents</article-title><source>Am Heart J</source><year>2009</year><month>10</month><volume>158</volume><issue>4</issue><fpage>592</fpage><lpage>598.e1</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2009.06.030</pub-id><pub-id pub-id-type="medline">19781419</pub-id><!--<pub-id pub-id-type="pii">S0002-8703(09)00543-2</pub-id>--><pub-id pub-id-type="pmid">19781419</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neugaard</surname><given-names>BI</given-names></name><name><surname>Priest</surname><given-names>JL</given-names></name><name><surname>Burch</surname><given-names>SP</given-names></name><name><surname>Cantrell</surname><given-names>CR</given-names></name><name><surname>Foulis</surname><given-names>PR</given-names></name></person-group><article-title>Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization</article-title><source>Popul Health Manag</source><year>2011</year><month>4</month><volume>14</volume><issue>2</issue><fpage>99</fpage><lpage>106</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/21091367"/></comment><pub-id pub-id-type="doi">10.1089/pop.2010.0020</pub-id><pub-id pub-id-type="medline">21091367</pub-id><!--<pub-id pub-id-type="pmcid">PMC3128447</pub-id>--><pub-id pub-id-type="pmid">21091367</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roughead</surname><given-names>EE</given-names></name><name><surname>Vitry</surname><given-names>AI</given-names></name><name><surname>Preiss</surname><given-names>AK</given-names></name><name><surname>Barratt</surname><given-names>JD</given-names></name><name><surname>Gilbert</surname><given-names>AL</given-names></name><name><surname>Ryan</surname><given-names>P</given-names></name></person-group><article-title>Assessing overall duration of cardiovascular medicines in veterans with established cardiovascular disease</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2010</year><month>2</month><volume>17</volume><issue>1</issue><fpage>71</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/HJR.0b013e32832f3b56</pub-id><pub-id pub-id-type="medline">19587601</pub-id><pub-id pub-id-type="pmid">19587601</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>WH</given-names></name><name><surname>Kazis</surname><given-names>LE</given-names></name><name><surname>Miller</surname><given-names>DR</given-names></name><name><surname>Skinner</surname><given-names>KM</given-names></name><name><surname>Clark</surname><given-names>JA</given-names></name><name><surname>Spiro</surname><given-names>A</given-names></name><name><surname>Fincke</surname><given-names>RG</given-names></name></person-group><article-title>Comparing the health status of VA and non-VA ambulatory patients: the veterans' health and medical outcomes studies</article-title><source>J Ambul Care Manage</source><year>2004</year><volume>27</volume><issue>3</issue><fpage>249</fpage><lpage>62</lpage><pub-id pub-id-type="medline">15287215</pub-id><pub-id pub-id-type="pmid">15287215</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterberg</surname><given-names>L</given-names></name><name><surname>Blaschke</surname><given-names>T</given-names></name></person-group><article-title>Adherence to medication</article-title><source>N Engl J Med</source><year>2005</year><month>8</month><day>4</day><volume>353</volume><issue>5</issue><fpage>487</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1056/NEJMra050100</pub-id><pub-id pub-id-type="medline">16079372</pub-id><!--<pub-id pub-id-type="pii">353/5/487</pub-id>--><pub-id pub-id-type="pmid">16079372</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sabat&#x000e9;</surname><given-names>E</given-names></name></person-group><source>World Health Organization</source><year>2003</year><date-in-citation>2013-03-13</date-in-citation><publisher-loc>Switzerland</publisher-loc><publisher-name>World Health Organization</publisher-name><comment>Adherence to long-term therapies: evidence for action
<ext-link ext-link-type="uri" xlink:href="http://www.who.int/chp/knowledge/publications/adherence_report/en/">http://www.who.int/chp/knowledge/publications/adherence_report/en/</ext-link><ext-link ext-link-type="webcite" xlink:href="9241545992"/></comment></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar-Jacob</surname><given-names>J</given-names></name><name><surname>Bohachick</surname><given-names>P</given-names></name><name><surname>Mortimer</surname><given-names>MK</given-names></name><name><surname>Sereika</surname><given-names>SM</given-names></name><name><surname>Foley</surname><given-names>SM</given-names></name></person-group><article-title>Medication adherence in persons with cardiovascular disease</article-title><source>J Cardiovasc Nurs</source><year>2003</year><volume>18</volume><issue>3</issue><fpage>209</fpage><lpage>18</lpage><pub-id pub-id-type="medline">12837011</pub-id><pub-id pub-id-type="pmid">12837011</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>PM</given-names></name><name><surname>Magid</surname><given-names>DJ</given-names></name><name><surname>Shetterly</surname><given-names>SM</given-names></name><name><surname>Olson</surname><given-names>KL</given-names></name><name><surname>Maddox</surname><given-names>TM</given-names></name><name><surname>Peterson</surname><given-names>PN</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name></person-group><article-title>Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease</article-title><source>Am Heart J</source><year>2008</year><month>4</month><volume>155</volume><issue>4</issue><fpage>772</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2007.12.011</pub-id><pub-id pub-id-type="medline">18371492</pub-id><!--<pub-id pub-id-type="pii">S0002-8703(07)01035-6</pub-id>--><pub-id pub-id-type="pmid">18371492</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garner</surname><given-names>JB</given-names></name></person-group><article-title>Problems of nonadherence in cardiology and proposals to improve outcomes</article-title><source>Am J Cardiol</source><year>2010</year><month>5</month><day>15</day><volume>105</volume><issue>10</issue><fpage>1495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2009.12.077</pub-id><pub-id pub-id-type="medline">20451702</pub-id><!--<pub-id pub-id-type="pii">S0002-9149(10)00089-5</pub-id>--><pub-id pub-id-type="pmid">20451702</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>New England Health Institute</collab></person-group><source>New England Healthcare Institute</source><year>2009</year><month>8</month><day>11</day><date-in-citation>2009-10-30</date-in-citation><publisher-loc>New England</publisher-loc><comment>Research shows patient medication nonadherence costs health care system $290 billion annually
<ext-link ext-link-type="uri" xlink:href="http://www.nehi.net/news/344-nehi-research-shows-patient-medication-nonadherence-costs-health-care-system-290-billion-annually/view">http://www.nehi.net/news/344-nehi-research-shows-patient-medication-nonadherence-costs-health-care-system-290-billion-annually/view</ext-link><ext-link ext-link-type="webcite" xlink:href="6rZFY7LsE"/></comment></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teyhen</surname><given-names>DS</given-names></name><name><surname>Aldag</surname><given-names>M</given-names></name><name><surname>Centola</surname><given-names>D</given-names></name><name><surname>Edinborough</surname><given-names>E</given-names></name><name><surname>Ghannadian</surname><given-names>JD</given-names></name><name><surname>Haught</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>T</given-names></name><name><surname>Kinn</surname><given-names>J</given-names></name><name><surname>Kunkler</surname><given-names>KJ</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Martindale</surname><given-names>VE</given-names></name><name><surname>Neal</surname><given-names>D</given-names></name><name><surname>Snyder</surname><given-names>LB</given-names></name><name><surname>Styn</surname><given-names>MA</given-names></name><name><surname>Thorndike</surname><given-names>F</given-names></name><name><surname>Trabosh</surname><given-names>V</given-names></name><name><surname>Parramore</surname><given-names>DJ</given-names></name></person-group><article-title>Incentives to create and sustain healthy behaviors: technology solutions and research needs</article-title><source>Mil Med</source><year>2014</year><month>12</month><volume>179</volume><issue>12</issue><fpage>1419</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.7205/MILMED-D-14-00111</pub-id><pub-id pub-id-type="medline">25469962</pub-id><pub-id pub-id-type="pmid">25469962</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>RB</given-names></name><name><surname>Ackloo</surname><given-names>E</given-names></name><name><surname>Sahota</surname><given-names>N</given-names></name><name><surname>McDonald</surname><given-names>HP</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name></person-group><article-title>Interventions for enhancing medication adherence</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><issue>2</issue><fpage>CD000011</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD000011.pub3</pub-id><pub-id pub-id-type="medline">18425859</pub-id><pub-id pub-id-type="pmid">18425859</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>PM</given-names></name><name><surname>Bryson</surname><given-names>CL</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name></person-group><article-title>Medication adherence: its importance in cardiovascular outcomes</article-title><source>Circulation</source><year>2009</year><month>6</month><day>16</day><volume>119</volume><issue>23</issue><fpage>3028</fpage><lpage>35</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://circ.ahajournals.org/cgi/pmidlookup?view=long&#x00026;pmid=19528344"/></comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.768986</pub-id><pub-id pub-id-type="medline">19528344</pub-id><!--<pub-id pub-id-type="pii">119/23/3028</pub-id>--><pub-id pub-id-type="pmid">19528344</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosworth</surname><given-names>HB</given-names></name><name><surname>Granger</surname><given-names>BB</given-names></name><name><surname>Mendys</surname><given-names>P</given-names></name><name><surname>Brindis</surname><given-names>R</given-names></name><name><surname>Burkholder</surname><given-names>R</given-names></name><name><surname>Czajkowski</surname><given-names>SM</given-names></name><name><surname>Daniel</surname><given-names>JG</given-names></name><name><surname>Ekman</surname><given-names>I</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Kimmel</surname><given-names>SE</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Musaus</surname><given-names>J</given-names></name><name><surname>Shrank</surname><given-names>WH</given-names></name><name><surname>Whalley</surname><given-names>BE</given-names></name><name><surname>Weiss</surname><given-names>K</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name></person-group><article-title>Medication adherence: a call for action</article-title><source>Am Heart J</source><year>2011</year><month>9</month><volume>162</volume><issue>3</issue><fpage>412</fpage><lpage>24</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/21884856"/></comment><pub-id pub-id-type="doi">10.1016/j.ahj.2011.06.007</pub-id><pub-id pub-id-type="medline">21884856</pub-id><!--<pub-id pub-id-type="pii">S0002-8703(11)00475-3</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3947508</pub-id>--><pub-id pub-id-type="pmid">21884856</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MT</given-names></name><name><surname>Bussell</surname><given-names>JK</given-names></name></person-group><article-title>Medication adherence: WHO cares?</article-title><source>Mayo Clin Proc</source><year>2011</year><month>4</month><volume>86</volume><issue>4</issue><fpage>304</fpage><lpage>14</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/21389250"/></comment><pub-id pub-id-type="doi">10.4065/mcp.2010.0575</pub-id><pub-id pub-id-type="medline">21389250</pub-id><!--<pub-id pub-id-type="pii">S0025-6196(11)60007-4</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3068890</pub-id>--><pub-id pub-id-type="pmid">21389250</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMullen</surname><given-names>CK</given-names></name><name><surname>Safford</surname><given-names>MM</given-names></name><name><surname>Bosworth</surname><given-names>HB</given-names></name><name><surname>Phansalkar</surname><given-names>S</given-names></name><name><surname>Leong</surname><given-names>A</given-names></name><name><surname>Fagan</surname><given-names>MB</given-names></name><name><surname>Trontell</surname><given-names>A</given-names></name><name><surname>Rumptz</surname><given-names>M</given-names></name><name><surname>Vandermeer</surname><given-names>ML</given-names></name><collab>Centers for Education and Research on Therapeutics Patient-Centered Medication Management Workshop Working Group</collab><name><surname>Brinkman</surname><given-names>WB</given-names></name><name><surname>Burkholder</surname><given-names>R</given-names></name><name><surname>Frank</surname><given-names>L</given-names></name><name><surname>Hommel</surname><given-names>K</given-names></name><name><surname>Mathews</surname><given-names>R</given-names></name><name><surname>Hornbrook</surname><given-names>MC</given-names></name><name><surname>Seid</surname><given-names>M</given-names></name><name><surname>Fordis</surname><given-names>M</given-names></name><name><surname>Lambert</surname><given-names>B</given-names></name><name><surname>McElwee</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>JA</given-names></name></person-group><article-title>Patient-centered priorities for improving medication management and adherence</article-title><source>Patient Educ Couns</source><year>2015</year><month>1</month><volume>98</volume><issue>1</issue><fpage>102</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2014.09.015</pub-id><pub-id pub-id-type="medline">25448313</pub-id><!--<pub-id pub-id-type="pii">S0738-3991(14)00405-4</pub-id>--><pub-id pub-id-type="pmid">25448313</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Nilsen</surname><given-names>WJ</given-names></name><name><surname>Abernethy</surname><given-names>A</given-names></name><name><surname>Atienza</surname><given-names>A</given-names></name><name><surname>Patrick</surname><given-names>K</given-names></name><name><surname>Pavel</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>WT</given-names></name><name><surname>Shar</surname><given-names>A</given-names></name><name><surname>Spring</surname><given-names>B</given-names></name><name><surname>Spruijt-Metz</surname><given-names>D</given-names></name><name><surname>Hedeker</surname><given-names>D</given-names></name><name><surname>Honavar</surname><given-names>V</given-names></name><name><surname>Kravitz</surname><given-names>R</given-names></name><name><surname>Lefebvre</surname><given-names>RC</given-names></name><name><surname>Mohr</surname><given-names>DC</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name><name><surname>Quinn</surname><given-names>C</given-names></name><name><surname>Shusterman</surname><given-names>V</given-names></name><name><surname>Swendeman</surname><given-names>D</given-names></name></person-group><article-title>Mobile health technology evaluation: the mHealth evidence workshop</article-title><source>Am J Prev Med</source><year>2013</year><month>8</month><volume>45</volume><issue>2</issue><fpage>228</fpage><lpage>36</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/23867031"/></comment><pub-id pub-id-type="doi">10.1016/j.amepre.2013.03.017</pub-id><pub-id pub-id-type="medline">23867031</pub-id><!--<pub-id pub-id-type="pii">S0749-3797(13)00277-8</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3803146</pub-id>--><pub-id pub-id-type="pmid">23867031</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>V</given-names></name><name><surname>Waller</surname><given-names>A</given-names></name><name><surname>Pagliari</surname><given-names>C</given-names></name><name><surname>Greene</surname><given-names>S</given-names></name></person-group><article-title>&#x0201c;Sweet Talk&#x0201d;: text messaging support for intensive insulin therapy for young people with diabetes</article-title><source>Diabetes Technol Ther</source><year>2003</year><volume>5</volume><issue>6</issue><fpage>991</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1089/152091503322641042</pub-id><pub-id pub-id-type="medline">14709202</pub-id><pub-id pub-id-type="pmid">14709202</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocosila</surname><given-names>M</given-names></name><name><surname>Archer</surname><given-names>N</given-names></name><name><surname>Haynes</surname><given-names>RB</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>Can wireless text messaging improve adherence to preventive activities? Results of a randomised controlled trial</article-title><source>Int J Med Inform</source><year>2009</year><month>4</month><volume>78</volume><issue>4</issue><fpage>230</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ijmedinf.2008.07.011</pub-id><pub-id pub-id-type="medline">18778967</pub-id><!--<pub-id pub-id-type="pii">S1386-5056(08)00130-5</pub-id>--><pub-id pub-id-type="pmid">18778967</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>LG</given-names></name><name><surname>Howie-Esquivel</surname><given-names>J</given-names></name><name><surname>Dracup</surname><given-names>K</given-names></name></person-group><article-title>A quantitative systematic review of the efficacy of mobile phone interventions to improve medication adherence</article-title><source>J Adv Nurs</source><year>2014</year><month>9</month><volume>70</volume><issue>9</issue><fpage>1932</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/jan.12400</pub-id><pub-id pub-id-type="medline">24689978</pub-id><pub-id pub-id-type="pmid">24689978</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>K</given-names></name><name><surname>Griswold</surname><given-names>WG</given-names></name><name><surname>Raab</surname><given-names>F</given-names></name><name><surname>Intille</surname><given-names>SS</given-names></name></person-group><article-title>Health and the mobile phone</article-title><source>Am J Prev Med</source><year>2008</year><month>8</month><volume>35</volume><issue>2</issue><fpage>177</fpage><lpage>81</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/18550322"/></comment><pub-id pub-id-type="doi">10.1016/j.amepre.2008.05.001</pub-id><pub-id pub-id-type="medline">18550322</pub-id><!--<pub-id pub-id-type="pii">S0749-3797(08)00407-8</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC2527290</pub-id>--><pub-id pub-id-type="pmid">18550322</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>WT</given-names></name><name><surname>Rivera</surname><given-names>DE</given-names></name><name><surname>Atienza</surname><given-names>AA</given-names></name><name><surname>Nilsen</surname><given-names>W</given-names></name><name><surname>Allison</surname><given-names>SM</given-names></name><name><surname>Mermelstein</surname><given-names>R</given-names></name></person-group><article-title>Health behavior models in the age of mobile interventions: are our theories up to the task?</article-title><source>Transl Behav Med</source><year>2011</year><month>3</month><volume>1</volume><issue>1</issue><fpage>53</fpage><lpage>71</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/21796270"/></comment><pub-id pub-id-type="doi">10.1007/s13142-011-0021-7</pub-id><pub-id pub-id-type="medline">21796270</pub-id><!--<pub-id pub-id-type="pii">21</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3142960</pub-id>--><pub-id pub-id-type="pmid">21796270</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pharow</surname><given-names>P</given-names></name><name><surname>Blobel</surname><given-names>B</given-names></name><name><surname>Ruotsalainen</surname><given-names>P</given-names></name><name><surname>Petersen</surname><given-names>F</given-names></name><name><surname>Hovsto</surname><given-names>A</given-names></name></person-group><article-title>Portable devices, sensors and networks: wireless personalized eHealth services</article-title><source>Stud Health Technol Inform</source><year>2009</year><volume>150</volume><fpage>1012</fpage><lpage>6</lpage><pub-id pub-id-type="medline">19745466</pub-id><pub-id pub-id-type="pmid">19745466</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>LG</given-names></name><name><surname>Howie-Esquivel</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>ML</given-names></name><name><surname>Dracup</surname><given-names>K</given-names></name></person-group><article-title>A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial</article-title><source>Patient Educ Couns</source><year>2014</year><month>2</month><volume>94</volume><issue>2</issue><fpage>261</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2013.10.027</pub-id><pub-id pub-id-type="medline">24321403</pub-id><!--<pub-id pub-id-type="pii">S0738-3991(13)00468-0</pub-id>--><pub-id pub-id-type="pmid">24321403</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>CM</given-names></name><name><surname>Collins Sharp</surname><given-names>BA</given-names></name></person-group><article-title>Women's health during health care transformation</article-title><source>J Gen Intern Med</source><year>2013</year><month>7</month><volume>28 Suppl 2</volume><fpage>S500</fpage><lpage>3</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/23807056"/></comment><pub-id pub-id-type="doi">10.1007/s11606-013-2473-6</pub-id><pub-id pub-id-type="medline">23807056</pub-id><!--<pub-id pub-id-type="pmcid">PMC3695281</pub-id>--><pub-id pub-id-type="pmid">23807056</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doshi</surname><given-names>A</given-names></name><name><surname>Patrick</surname><given-names>K</given-names></name><name><surname>Sallis</surname><given-names>JF</given-names></name><name><surname>Calfas</surname><given-names>K</given-names></name></person-group><article-title>Evaluation of physical activity web sites for use of behavior change theories</article-title><source>Ann Behav Med</source><year>2003</year><volume>25</volume><issue>2</issue><fpage>105</fpage><lpage>11</lpage><pub-id pub-id-type="medline">12704012</pub-id><pub-id pub-id-type="pmid">12704012</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azar</surname><given-names>KM</given-names></name><name><surname>Lesser</surname><given-names>LI</given-names></name><name><surname>Laing</surname><given-names>BY</given-names></name><name><surname>Stephens</surname><given-names>J</given-names></name><name><surname>Aurora</surname><given-names>MS</given-names></name><name><surname>Burke</surname><given-names>LE</given-names></name><name><surname>Palaniappan</surname><given-names>LP</given-names></name></person-group><article-title>Mobile applications for weight management: theory-based content analysis</article-title><source>Am J Prev Med</source><year>2013</year><month>11</month><volume>45</volume><issue>5</issue><fpage>583</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2013.07.005</pub-id><pub-id pub-id-type="medline">24139771</pub-id><!--<pub-id pub-id-type="pii">S0749-3797(13)00431-5</pub-id>--><pub-id pub-id-type="pmid">24139771</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>J</given-names></name></person-group><source>Smart Phone Applications for People with Brain Injury</source><year>1986</year><date-in-citation>2015-01-02</date-in-citation><publisher-loc>United Kingdom</publisher-loc><publisher-name>Agency for Clinical Innovation</publisher-name><comment>The project implementing and evaluating smart phone applications technology across the NSW Brain Injury Rehabilitation Program (BIRP)
<ext-link ext-link-type="uri" xlink:href="http://www.tbistafftraining.info/smartphones/documents/b5_during_the_trial_usability_scale_v1_09aug11.pdf">http://www.tbistafftraining.info/smartphones/documents/b5_during_the_trial_usability_scale_v1_09aug11.pdf</ext-link><ext-link ext-link-type="webcite" xlink:href="6rZhP15dA"/></comment></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Frayne</surname><given-names>S</given-names></name><name><surname>Phibbs</surname><given-names>C</given-names></name><name><surname>Friedman</surname><given-names>S</given-names></name><name><surname>Berg</surname><given-names>E</given-names></name><name><surname>Ananth</surname><given-names>L</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>P</given-names></name><name><surname>Herrera</surname><given-names>L</given-names></name></person-group><source>Sourcebook: Women Veterans in the Veterans Health Administration. Volume 1</source><year>2010</year><month>12</month><date-in-citation>2017-06-28</date-in-citation><publisher-loc>Washington DC</publisher-loc><publisher-name>Women&#x02019;s Health Evaluation Initiative, Women Veterans Health Strategic Health Care Group, Veterans Health Administration, Department of Veterans Affairs</publisher-name><comment>Sociodemographic characteristics and utilization of VHA care
<ext-link ext-link-type="uri" xlink:href="https://www.research.va.gov/media_roundtable/Sourcebook.pdf">https://www.research.va.gov/media_roundtable/Sourcebook.pdf</ext-link><ext-link ext-link-type="webcite" xlink:href="6rZGBHLjt"/></comment></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carolan Doerflinger</surname><given-names>DM</given-names></name></person-group><article-title>How to try this: the mini-cog</article-title><source>Am J Nurs</source><year>2007</year><month>12</month><volume>107</volume><issue>12</issue><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/01.NAJ.0000301030.81651.66</pub-id><pub-id pub-id-type="medline">18049065</pub-id><!--<pub-id pub-id-type="pii">00000446-200712000-00031</pub-id>--><pub-id pub-id-type="pmid">18049065</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ailinger</surname><given-names>RL</given-names></name><name><surname>Black</surname><given-names>PL</given-names></name><name><surname>Lima-Garcia</surname><given-names>N</given-names></name></person-group><article-title>Use of electronic monitoring in clinical nursing research</article-title><source>Clin Nurs Res</source><year>2008</year><month>5</month><volume>17</volume><issue>2</issue><fpage>89</fpage><lpage>97</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/18387881"/></comment><pub-id pub-id-type="doi">10.1177/1054773808316941</pub-id><pub-id pub-id-type="medline">18387881</pub-id><!--<pub-id pub-id-type="pii">17/2/89</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC2583405</pub-id>--><pub-id pub-id-type="pmid">18387881</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morisky</surname><given-names>DE</given-names></name><name><surname>Ang</surname><given-names>A</given-names></name><name><surname>Krousel-Wood</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>HJ</given-names></name></person-group><article-title>Predictive validity of a medication adherence measure in an outpatient setting</article-title><source>J Clin Hypertens (Greenwich)</source><year>2008</year><month>5</month><volume>10</volume><issue>5</issue><fpage>348</fpage><lpage>54</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/18453793"/></comment><pub-id pub-id-type="medline">18453793</pub-id><!--<pub-id pub-id-type="pmcid">PMC2562622</pub-id>--><pub-id pub-id-type="pmid">18453793</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalansky</surname><given-names>SJ</given-names></name><name><surname>Levy</surname><given-names>AR</given-names></name><name><surname>Ignaszewski</surname><given-names>AP</given-names></name></person-group><article-title>Self-reported Morisky score for identifying nonadherence with cardiovascular medications</article-title><source>Ann Pharmacother</source><year>2004</year><month>9</month><volume>38</volume><issue>9</issue><fpage>1363</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1345/aph.1E071</pub-id><pub-id pub-id-type="medline">15238622</pub-id><!--<pub-id pub-id-type="pii">aph.1E071</pub-id>--><pub-id pub-id-type="pmid">15238622</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Heart Association</collab></person-group><source>My Life Check - Life's Simple 7</source><year>2017</year><month>6</month><day>23</day><date-in-citation>2017-06-29</date-in-citation><publisher-loc>Dallas, TX</publisher-loc><publisher-name>American Heart Association</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.heart.org/HEARTORG/Conditions/My-Life-Check---Lifes-Simple-7_UCM_471453_Article.jsp">http://www.heart.org/HEARTORG/Conditions/My-Life-Check---Lifes-Simple-7_UCM_471453_Article.jsp</ext-link><ext-link ext-link-type="webcite" xlink:href="6rZhhZFc5"/></comment></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>J</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>SD</given-names></name></person-group><article-title>A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity</article-title><source>Med Care</source><year>1996</year><month>3</month><volume>34</volume><issue>3</issue><fpage>220</fpage><lpage>33</lpage><pub-id pub-id-type="medline">8628042</pub-id><pub-id pub-id-type="pmid">8628042</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherbourne</surname><given-names>CD</given-names></name><name><surname>Stewart</surname><given-names>AL</given-names></name></person-group><article-title>The MOS social support survey</article-title><source>Soc Sci Med</source><year>1991</year><volume>32</volume><issue>6</issue><fpage>705</fpage><lpage>14</lpage><pub-id pub-id-type="medline">2035047</pub-id><pub-id pub-id-type="pmid">2035047</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risser</surname><given-names>J</given-names></name><name><surname>Jacobson</surname><given-names>TA</given-names></name><name><surname>Kripalani</surname><given-names>S</given-names></name></person-group><article-title>Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease</article-title><source>J Nurs Meas</source><year>2007</year><volume>15</volume><issue>3</issue><fpage>203</fpage><lpage>19</lpage><pub-id pub-id-type="medline">18232619</pub-id><pub-id pub-id-type="pmid">18232619</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name></person-group><article-title>The PHQ-9: validity of a brief depression severity measure</article-title><source>J Gen Intern Med</source><year>2001</year><month>9</month><volume>16</volume><issue>9</issue><fpage>606</fpage><lpage>13</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/11556941"/></comment><pub-id pub-id-type="medline">11556941</pub-id><!--<pub-id pub-id-type="pii">jgi01114</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC1495268</pub-id>--><pub-id pub-id-type="pmid">11556941</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>L&#x000f6;we</surname><given-names>B</given-names></name></person-group><article-title>A brief measure for assessing generalized anxiety disorder: the GAD-7</article-title><source>Arch Intern Med</source><year>2006</year><month>5</month><day>22</day><volume>166</volume><issue>10</issue><fpage>1092</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1001/archinte.166.10.1092</pub-id><pub-id pub-id-type="medline">16717171</pub-id><!--<pub-id pub-id-type="pii">166/10/1092</pub-id>--><pub-id pub-id-type="pmid">16717171</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Weathers</surname><given-names>FW</given-names></name><name><surname>Litz</surname><given-names>BT</given-names></name><name><surname>Huska</surname><given-names>JA</given-names></name></person-group><source>US Department of Veteran Affairs</source><year>2003</year><month>12</month><date-in-citation>2017-06-28</date-in-citation><comment>PTSD checkList &#x02013; civilian version
<ext-link ext-link-type="uri" xlink:href="https://www.mirecc.va.gov/docs/visn6/3_PTSD_CheckList_and_Scoring.pdf">https://www.mirecc.va.gov/docs/visn6/3_PTSD_CheckList_and_Scoring.pdf</ext-link><ext-link ext-link-type="webcite" xlink:href="6rZF3Q5vY"/></comment></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsen</surname><given-names>W</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Shar</surname><given-names>A</given-names></name><name><surname>Varoquiers</surname><given-names>C</given-names></name><name><surname>Wiley</surname><given-names>T</given-names></name><name><surname>Riley</surname><given-names>WT</given-names></name><name><surname>Pavel</surname><given-names>M</given-names></name><name><surname>Atienza</surname><given-names>AA</given-names></name></person-group><article-title>Advancing the science of mHealth</article-title><source>J Health Commun</source><year>2012</year><volume>17 Suppl 1</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1080/10810730.2012.677394</pub-id><pub-id pub-id-type="medline">22548593</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klasnja</surname><given-names>P</given-names></name><name><surname>Pratt</surname><given-names>W</given-names></name></person-group><article-title>Healthcare in the pocket: mapping the space of mobile-phone health interventions</article-title><source>J Biomed Inform</source><year>2012</year><month>2</month><volume>45</volume><issue>1</issue><fpage>184</fpage><lpage>98</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/21925288"/></comment><pub-id pub-id-type="doi">10.1016/j.jbi.2011.08.017</pub-id><pub-id pub-id-type="medline">21925288</pub-id><!--<pub-id pub-id-type="pii">S1532-0464(11)00144-4</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3272165</pub-id>--><pub-id pub-id-type="pmid">21925288</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zullig</surname><given-names>LL</given-names></name><name><surname>Shaw</surname><given-names>RJ</given-names></name><name><surname>Shah</surname><given-names>BR</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Lindquist</surname><given-names>JH</given-names></name><name><surname>Crowley</surname><given-names>MJ</given-names></name><name><surname>Grambow</surname><given-names>SC</given-names></name><name><surname>Bosworth</surname><given-names>HB</given-names></name></person-group><article-title>Patient-provider communication, self-reported medication adherence, and race in a postmyocardial infarction population</article-title><source>Patient Prefer Adherence</source><year>2015</year><volume>9</volume><fpage>311</fpage><lpage>8</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.2147/PPA.S75393"/></comment><pub-id pub-id-type="doi">10.2147/PPA.S75393</pub-id><pub-id pub-id-type="medline">25737633</pub-id><!--<pub-id pub-id-type="pii">ppa-9-311</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC4344178</pub-id>--><pub-id pub-id-type="pmid">25737633</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuboyejo</surname><given-names>S</given-names></name><name><surname>Eyesan</surname><given-names>O</given-names></name></person-group><article-title>mHealth: using mobile technology to support healthcare</article-title><source>Online J Public Health Inform</source><year>2014</year><volume>5</volume><issue>3</issue><fpage>233</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/24678384"/></comment><pub-id pub-id-type="doi">10.5210/ojphi.v5i3.4865</pub-id><pub-id pub-id-type="medline">24678384</pub-id><!--<pub-id pub-id-type="pii">ojphi-05-e233</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3959917</pub-id>--><pub-id pub-id-type="pmid">24678384</pub-id></element-citation></ref></ref-list></back></article>